Patrick Campbell

Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension.

An analysis of FIGARO-DKD from Kidney Week 2021 suggests finerenone use was associated with reductions in risk of multiple renal end points, including a 36% reduction in the need for dialysis.

Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.

Data from the CLICK trial presented at ASN Kidney Week 2021 suggests the use of chlorthalidone could reduce blood pressure by 11 mmHg among patients with stage 4 chronic kidney disease and poorly controlled hypertension.

Using the Steno Type 1 Risk Engine, a team from Denmark conducted a study suggesting SGLT2 inhibition could lower risk of cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes.

An analysis of secondary end points from FIGARO-DKD presented at Kidney Week 2021 provides further insight into the effects of finerenone on kidney outcomes, including a 36% reduction in need for dialysis.

Results of the 5-year follow-up from SURTAVI, which were presented at TCT 2021, provide insight into the associations of TAVR with mortality and stroke compared to SAVR in patients with severe aortic stenosis considered to be at intermediate risk.

Results of the 6-month follow-up from RADIANCE-HTN TRIO suggest the addition of antihypertensive medications following renal denervation could contribute to further blood pressure lowering in patients with treatment-resistant hypertension.

Data from the FIDELITY analysis suggests use of finerenone was associated with a significant 20% reduction in end-stage kidney disease as well as reductions in all nonfatal kidney end points included in the study's composite kidney outcome.

Data from the FAME 3 trial cast doubt on the role of FFR-guided PCI versus CABG among patients with 3-vessel coronary artery disease.

Data presented at ACR Convergence 2021 suggest statin initiation was associated with a 32% reduction in risk of cardiovascular disease, 54% reduction in risk of all-cause mortality, and a 33% increase in risk of type 2 diabetes.

Results of the LIFE trial suggest sacubitril/valsartan failed to outperform valsartan alone for multiple end points of interest, including reductions of NT-proBNP.

An analysis of data from more than 160k adults with type 2 diabetes in Scotland provides insight into the incidence of diabetes remission and factors associated with increased likelihood of achieving remission.

A time-conditional propensity score-matched analysis suggests statin initiation was associated with reductions in risk of cardiovascular disease and all-cause mortality but an increase in the risk of new diabetes in patients with rheumatoid arthritis.

A propensity score-matched analysis comparing fracture risk associated with the initiation of SGLT2 inhibitors versus GLP-1RAs or DPP-4 inhibitors indicates use of SGLT2 inhibitors was not associated with an increase in risk of fractures in older patients with type 2 diabetes.

An analysis of data from multiple Danish registries provides evidence suggesting women who experience preterm delivery had 1.6-fold greater odds of developing hypertension later in life.

An analysis of more than 2.4 million offspring in Denmark suggests children with exposure to maternal diabetes during pregnancy were at a 15% greater risk of developing a psychiatric disorder in the first 40 years of life.

An analysis of data from 14.6k patients with T1D using flash monitoring provides insights into the effects of the technology on HbA1c as well as rates of DKA and hospitalizations for hypoglycemia.

New research suggests use of mobile technology could help improve blood pressure over a long-term period, with greater engagement with the technology associated with greater improvements in blood pressure.

A pair of studies provide insight into the increased risk of dysglycemia among women with PCOS and the potential influence of combined oral contraceptive pills on this risk in a population-based cohort.

A multicenter case-control study of a trio of hospitals in Spain suggests the presence of diabetes was not associated with an increased risk of long-term COVID-19 symptoms.

An analysis of more than 4 million singleton deliveries from more than 2.1 million women provides insight into the apparent increase in risk associated with preterm delivery.

In an analysis of SWAN data, investigators found changes in menstrual cycle length within the 5 years preceding a woman's final menstrual period was associated with changes in carotid intima-media thickness and brachial-ankle pulse wave velocity.

An analysis of 5 years of follow-up data from more than 90k Medicare beneficiaries suggests undergoing sleeve gastrectomy was associated with lower risk of mortality, complications, and reintervention, but an increased risk of surgical revision compared to gastric bypass.

A comparison of data from expansion states and nonexpansion states suggests access to bariatric surgery has increased since the ACA Medicaid expansion, but the increase in access has been limited mainly to non-Hispanic White patients.

Analysis of data from 83k matched pairs suggests statin initiation could increase a patient's odds of diabetes progression, including need for new glucose-lowering medications and new insulin use.

Leveraging data from 3 European cohorts, investigators detail the risk of incident coronary heart disease and mortality associated with iron deficiency in the general population.

An analysis of nearly 400 patients suggests undergoing thyroid radiofrequency ablation in ambulatory settings was associated with increased risk of intraoperative, postoperative, and perioperative side effects than those performed in operating room settings.

A meta-analysis and systematic review of 7 RCTs suggests consuming more than 1 gram of marine omega-3 fatty acid supplements per day could increase a patient's risk of atrial fibrillation.

An analysis of more than 1.2 million patients who experienced a fracture from 1997-2017 provides insight into contemporary trends in fracture incidence rates based on presence of diabetes.